Belina Yi, D.O. | Pediatric Rheumatologist
Why It Matters
Recognizing and treating pediatric autoimmune diseases early improves lifelong health, while Dr. Yi’s research and collaborative model set a benchmark for specialized, evidence‑based pediatric rheumatology care.
Key Takeaways
- •Children can develop arthritis and systemic autoimmune diseases.
- •Dr. Yi focuses on juvenile dermatomyositis and calcinosis research.
- •Treatment emphasizes individualized, evidence‑based care for varied presentations.
- •Collaborative multidisciplinary approach at Johns Hopkins enhances patient outcomes.
- •Ongoing clinical research informs latest medication and assessment tools.
Summary
The video introduces Dr. Bellina Yi, a pediatric rheumatologist at Johns Hopkins Children’s Center, who treats children with autoimmune and autoinflammatory diseases. She emphasizes that, unlike common perception, arthritis and systemic conditions can affect patients from infancy through adolescence.
Dr. Yi outlines the spectrum of illnesses she manages, including juvenile idiopathic arthritis, systemic lupus erythematosus, and her primary focus—juvenile dermatomyositis, a disease that inflames skin, muscle, and internal organs. Her research concentrates on dermatomyositis‑related calcinosis, aiming to refine diagnostic tools and therapeutic options.
She repeatedly stresses the privilege of working with children and their families, noting that individualized, evidence‑based treatment is essential because presentations vary widely. The collaborative environment at Johns Hopkins, involving multiple specialists, enables her to stay current with cutting‑edge medications and assessment protocols.
The broader implication is heightened awareness that pediatric patients can suffer from serious rheumatologic conditions and that dedicated, multidisciplinary care—bolstered by ongoing research—can dramatically improve outcomes and quality of life for these young patients.
Comments
Want to join the conversation?
Loading comments...